AstraZeneca

Forecast & Rating10 analysts currently cover AstraZeneca, with about 90.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $213.69, about 36.6% upside from the current price of $156.45. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 97.4% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study AstraZeneca closely still see room for the stock to rise. Data as of Aug 10, 2026; for reference only and not investment advice.